VTAMA cream can give plaque psoriasis patients significantly clearer skin.

So they’re free to think about… literally anything.

VTAMA® (tapinarof) cream, 1% is a first-in-class topical treatment for adults with plaque psoriasis. It’s an Aryl hydrocarbon Receptor (AhR) agonist that could change the approach to plaque psoriasis treatment.1,2

prescribed branded topical treatment for plaque psoriasis in adults
*IQVIA National Prescription Audit (NPA) for the 3-month period ending 10/28/2022, reflecting estimates of real-world activity. All rights reserved.
  • 6x the Efficacy vs Vehicle
    In two 12-week pivotal studies, the Physician Global Assessment (PGA) success* rate was 36% and 40% for patients using VTAMA cream vs 6% and 6% for patients on vehicle.1
  • Favorable Safety and Tolerability
    In clinical studies, VTAMA cream showed a favorable and consistent safety profile and was well tolerated, even on sensitive areas of skin.3,4
  • ~4 Month Off-Treatment Effect
    In an open-label, long-term extension study, the median time to first disease worsening (defined as PGA≥2 [mild]) was 114 days (n=73)(95% CI: 85, 142).1
*PGA success: PGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.
what patients from clinical studies
said about VTAMA cream
VTAMA® Cream and Droplet
~90% of patients said VTAMA cream is easy to apply, non-greasy, and absorbs quickly5
Checkmark next to VTAMA® Cream
84% of patients would recommend VTAMA cream to others if available5
Thumbs-up icon
83% of patients said they would use VTAMA cream again or continue to use treatment5